The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
Philip Bredin, Jarushka Naidoo
Abstract
Systemic treatment options for patients with lung cancer have expanded in recent years, with a number of immunotherapeutic strategies now in our treatment armamentarium. Toxicity of and resistance to treatment hold a major stake in lung cancer morbidity and mortality. Herein, we summarise the background, current evidence and potential mechanisms underlying the role of the commensal gut microbiota in immunotherapy outcomes such as response and toxicity in patients with non-small cell lung cancer (NSCLC).
Topics & Concepts
Lung cancerImmune systemImmunotherapyMicrobiomeMedicineCancerImmunologyAdverse effectToxicityOncologyInternal medicineBioinformaticsBiologyCancer Immunotherapy and BiomarkersGut microbiota and healthCancer, Stress, Anesthesia, and Immune Response